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OBJECTIVE—To estimate, among privately insured youth in the U.S., medical expenditures
associated with diabetes and the difference in medical expenditures between individuals with
insulin-treated diabetes mellitus (ITDM) and with non-ITDM (NITDM).
RESEARCH DESIGN AND METHODS—Using the 2007 MarketScan commercial
claims and encounter database, we analyzed data for 49,356 youth (aged #19 years) who were
continuously enrolled in fee-for-service health plans. Youth with diabetes (cases) were identiﬁed
from inpatient, outpatient, and pharmaceutical drug claims. Each case was matched with ﬁve
controls (without diabetes) by age (62 years), sex, census region, and urban versus rural resi-
dence. We used regression models to estimate medical expenditures in total and by component
(inpatient, outpatient, and medication).
RESULTS—The predicted mean annual total per-person medical expenditures were $9,061
foryouthwithdiabetesand$1,468forthosewithout,anexcessof$7,593forthosewithdiabetes;
of which, 43% was for prescription drugs. The predicted mean annual total expenditures were
$9,333forITDMyouthand$5,683forNITDMyouth,respectively,anexcessof$3,650forthose
with ITDM diabetes, of which 59% was for prescription drugs.
CONCLUSIONS—The excess medical expenditures associated with diabetes, ITDM in par-
ticular, among youth are substantial. Our estimates of excess expenditures can be used to assess
the economic burden of diabetes overall and by diabetes treatment mode. Our estimated excess
expenditure for NITDM may be used for evaluating the economic efﬁciency of interventions
aimed at preventing type 2 diabetes in U.S. youth.
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D
iabetes is one of the most prevalent
chronicdiseasesamongU.S.youth.
In2001,anestimated1.8per1,000
individuals aged ,20 years in the U.S.
had diabetes (1). An increase in the inci-
dence of type 1 diabetes, the most com-
mon form of diabetes in the young, has
been reported in Europe and the U.S.
(2,3). Furthermore, with increasing obe-
sity rates in the young, type 2 diabetes,
once considered an adult disorder, now
occurs in adolescents, especially in mi-
nority populations (4).
B e s i d e si t sa d v e r s ee f f e c t so na ni n d i v i d -
ual’s health and quality-of-life, diabetes also
imposes a staggering ﬁnancial burden on
the health care system. Numerous studies
have estimated the medical costs of diabe-
tes among adults or for the entire U.S. di-
abetic population (5–7). A few studies
have also estimated the direct medical ex-
penditures of diabetes among children
and adolescents in European countries
(8,9), as has one study in the U.S. (10).
However, the U.S. study was based on a
small sample of hospital patients.
Estimates of the direct medical costs
attributed to diabetes among youth are
essential to assess the ﬁnancial burden of
the disease and plan for future health care
needs. In addition, because type 2 di-
abetes is potentially preventable (11), es-
timates of medical expenditures are
needed to assess the full economic effect
of programs aimed to prevent type 2 di-
abetes in youth.
Our study’so b j e c t i v e sw e r et oe s t i -








We analyzed data from the MarketScan
Commercial Claims and Encounters
Database (CCE) (MarketScan Database;
Thompson Medstat, Ann Arbor, MI).
Widelyusedtoestimatethehealthexpen-
dituresofvariousillnesses—includingdi-
abetes among adults (6,12,13)—the CCE
database annually compiles fully adjudi-
cated and paid health insurance claims
from more than 100 large employers and
healthplans.Theclaimscomefromseveral
million individuals, including employees,
their spouses, and dependents, who are
covered by employer-sponsored private
health insurance (14). The CCE includes
p a t i e n t - l e v e ld a t ao ni n p a t i e n t ,o u t p a t i e n t ,
and drug claims. All three can be linked
through encrypted and unique enrollee
identiﬁers (15).
Enrollee health plans are divided into
fee-for-service (FFS) plans and fully or
partially capitated plans. FFS plans in-
clude preferred provider organization
(PPO) plans, exclusive provider orga-
nization plans, point-of-service plans,
consumer-directed health plans, and in-
demnity plans. Fully or partially capitated
plans include health maintenance orga-
nizations and point-of-service plans with
capitation (15).
Study population
We restricted our analyses to 3,366,791
youth aged #19 years who were contin-
uously enrolled in FFS health plans with
prescription drug coverage from 1 January
through 30 December 2007 (Fig. 1). We
limited our analysis to individuals enrolled
inFFSplansbecausetheirinsuranceclaims
represent actual payment for the services,
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ORIGINAL ARTICLEwhereas payment records in capitated
plans often only reﬂect encounters (15).
We excluded 0.5% of the youth because
ofmissingrecordsforcensusregion(north-
east, midwest, south, and west) or resi-
dence (rural vs. urban).
We identiﬁed an individual as having
diabetes if the record showed 1)a tl e a s t
two outpatient encounters that were at
least 30 days apart, coded for diabetes
as a primary or secondary diagnosis
(16),or2)atleastoneinpatientadmission
codedfordiabetesasaprimaryorsecond-
ary diagnosis, and 3) at least one pharma-
ceutical drug claim ﬁlled for insulin or
oral hypoglycemic agents, or both. The
requirement for at least two outpatient
encounters protected against inclusion
of youth who were misdiagnosed at the
ﬁrst encounter and were later determined
not to have diabetes (17). To indicate di-
abetes, we used the ICD-9-CM codes
250.00–250.93, 357.2, 362.0–362.02,
and 366.41 in outpatient and inpatient
claims (12,18) and the Therapeutic Class
Codes of 172, 173, and 174 in drug
claims. We identiﬁed 8,226 youth who
had diabetes.
Because the presence of other chronic
conditions could substantially inﬂuence
healthcareexpenditures,themodelshould
account for these conditions. Among
the 8,226 youth with diabetes, 4.6% had
asthma, the most commonly reported
chronic disease in youth, and we included
data on these individuals. A total of 159
youth (,2%) had one or more of the fol-
lowing uncommon chronic conditions:
congenital heart failure, hemiplegia, lym-
phoma, Down syndrome, autism, leuke-
mia, congenital heart defects, and liver
diseases. Because the number of observa-
tions for each of the uncommon chronic
conditions was too small to produce a re-
liable estimated coefﬁcient for that condi-
tion, we excluded data on these youth.
Remaining in our sample were 8,226
youth with diabetes.
We used bootstrapping to estimate
the SEs of predicted and excess mean
expenditures. Bootstrapping the entire
database of diabetes and without diabetic
youth exceeded our computation capac-
ity, so we used a case-control design to
reduce the sample size. Each youth with
diabetes (case subject) was directly matched
one-to-one with ﬁve youth without
diabetes (controlsubject),onthemultiple
variables: age (62 years), sex, U.S. census
region, and residence. For each case, con-
trol subjectswere selected fromarandom-
ized subset of combination of matching
variables without replacements. Each
case-control matched set was identiﬁed
as a unique cluster. Our analytic sample
comprised 49,356 youth.
Data limitations precluded us from
conclusively distinguishing type 1 and
type 2 diabetes. We distinguished youth
with diabetes by treatment mode (ITDM
vs. NITDM). Those who had at least one
prescription ﬁlled for insulin (Therapeutic
Class Code of 172) were identiﬁed as
having ITDM. By use of this method,
we identiﬁed 7,556 diabetic youth who
had ITDM. In contrast, remaining in our
sample were 670 individuals with di-
abetesbutwithoutinsulinprescriptions.
These youth were considered to have
NITDM.
Statistical analysis
We used t tests to assess differences in the
means of sample characteristics and com-
paredyouthwithdiabetesandthosewith-
out diabetes and youth with ITDM and
those with NITDM.
Estimation of expenditures: comparing
youth with and without diabetes. We
usedatwo-partmodel(19,20)toestimate
the excess medical expenditures associ-
ated with diabetes in total and by compo-
nent: outpatient, inpatient, and drug
expenditures. The two-part model was
used because a large proportion of the
nondiabeticyouthhadnomedicalexpendi-
tures, and among those who did, the med-
ical expenditures were right-skewed (19).
Intheﬁrstpartofthetwo-partmodel,
we estimated the probability that an in-
dividual would have a positive medical
expenditure. We used a generalized esti-
matingequation(GEE)withlogitlinkand
binomial distribution and accounted for
the dependence within matched sets
(clusters). In the second part, we esti-
mated the level of expenditures among
youth who had positive expenditures.
Here, we used a GEE model with log
link and g distribution, again accounting
forthedependencewithinthecluster.Be-
cause health plan type (PPO versus non-
PPO)andthepresenceofasthmawerenot
used in the case-control matching, we in-
cluded both as covariates. The main ex-
posure was a diagnosis of diabetes.
We calculated model-based predicted
marginal medical expenditures by diabetes
status. To estimate the predicted mar-
ginal medical expenditures associated
with diabetes, the diabetes indicator vari-
ablewasﬁrstsetto1forallindividualsand
then again to 0 for all individuals. All
other variables remained at their original
Figure 1—Selection of study sample. DM, diabetes mellitus.
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Medical expenditures of diabetes in youthvalues. For both indicator sets, individual
predicted values were calculated, and the
predictions were averaged over all obser-
vations. The difference in the predicted
mean expenditure between youth with
and without diabetes was the excess-
predicted expenditure associated with di-
abetes. We used 1,000 nonparametric
bootstrap replications of clusters to cal-
culate the SE of predicted and excess
expenditures (21).
Estimation of expenditures: comparing
youth by diabetes treatment mode. To
estimate medical expenditures in total
and by component associated with each
of the two diabetes treatment modes
(ITDM and NITDM), we used a two-part
model to estimate the inpatient expen-
ditures and only the second part of the
two-part model to estimate the total, out-
patient, and drug expenditures.
Estimation of the ﬁrst part ofthetwo-
part model was not needed for estimating
the total, outpatient, and drug expendi-
tures because all youth with diabetes had
positive expenditures for those compo-
nents.In estimatingtheinpatient expen-
ditures, similar to the model used for
estimating expenditures for youth with or
withoutdiabetesintheﬁrstpart,weuseda
logistic regression model to estimate the
probability of a youth having a nonzero
inpatient expenditure.
In the second part, we used a gener-
alized linear model with log link and a g
distribution to estimate the expenditures
among youth who had positive inpatient
expenditures. In estimating the total, out-
patient,anddrugexpenditures,weuseda
generalizedlinearmodelwithloglinkand
g distribution among all youth with dia-
betes.
For all models, we included age, sex,
U.S. census region, residence, health plan
type (PPO vs. non-PPO), and the pres-
ence of asthma as covariates. The pre-
dicted mean medical expenditures for
youth with ITDM and with NITDM and
predicted excess expenditure associated
with ITDM were estimated in the same
way as for youth with diabetes versus
without diabetes. We used 1,000 non-
parametric bootstrap replications to cal-
culate the SE of predicted and excess
expenditures.
Using the model-based predicted
mean annual expenditures, we calculated
ratios of per capita annual medical ex-
penditures in total and by component:
expenditures for youth with diabetes di-
vided by expenditures for those without
diabetes,and expendituresforyouthwith
ITDM divided by expenditures for those
with NITDM.
All analyses were performed using
STATA 10.1 software (StataCorp, College
Station, TX). We considered results sig-
niﬁcant at P , 0.05.
RESULTS
Characteristics of the study
population
Of the 49,356 youth, 15.2% had no med-
icalexpenditures,18.0%hadnooutpatient
expenditures, 95.9% had no inpatient ex-
penditures,and35.1%hadnoprescription
drug expenses. Of those identiﬁed with
diabetes,91.9%weretakinginsulin,alone
or combined with oral hypoglycemic
agents, and 84.0% had not been hospital-
ized during the year.
The characteristics of the study pop-
ulation by diabetes status and treatment
mode are summarized in Table 1. Among
y o u t hw i t hd i a b e t e s ,t h o s ew i t hI T D M
were signiﬁcantly younger (12.7 vs. 14.8
years; P , 0.05) and less likely to be girls
(47.7% vs. 67.5%; P , 0.05). Compared
with youth with NITDM, those with
ITDM were more likely to be from the
west (13.3% vs. 16.7%; P , 0.05) and
less likely to be from the south (52.1%
vs. 42.8%; P , 0.05). The percentage of
youth with asthma was signiﬁcantly
greater among those with NITDM than
among those with ITDM (9.7% vs.
4.1%; P , 0.05).
Medical expenditures associated
with diabetes
The predicted mean annual total medical
expenditure was $9,061 for youth with
diabetes and $1,468 for youth without
diabetes, an excess of $7,593 among di-
abeticyouth(P,0.05;Table2).Theout-
patient, inpatient, and drug expenditures
were all signiﬁcantly greater for diabetic
youth than those without (P , 0.05). Re-
gardless of diabetes status, outpatient
expenditures (43 and 66% for those
withorwithoutdiabetes,respectively)ac-
counted for the largest share of the total
expenditures, followed by prescription
drugs (39 and 19%, respectively) and
inpatient expenditures (18 and 15%,
respectively). However, excess expendi-
tures on prescription drugs accounted
for the largest proportion of the excess
total expenditures ($3,228; 43%), fol-
lowed by excess expenditures on outpa-
tient care ($2,970; 39%) and inpatient
care ($1,406; 19%). For youth with dia-
betes, the predicted mean expenditures
were $811 on diabetes supplies and
$1,688 on medications (data not shown).
Medical expenditures for youth
with ITDM and NITDM
The predicted mean total medical expen-
diture was $9,333 for youth with ITDM
and $5,683 for those with NITDM, an
excess of $3,650 (P , 0.05) for youth
with ITDM (Table 2). The three compo-
nent expenditures were all signiﬁcantly
greater for youth with ITDM than for
y o u t hw i t hN I T D M( P , 0.05). Regard-
less of treatment mode, the outpatient
expenditures comprised the largest share
of total expenditure (43 and 58%, respec-
tively, for ITDM and NITDM youth), fol-
lowed by prescription drugs (39 and
26%, respectively) and inpatient expen-
ditures (18 and 17%, respectively). How-
ever,ofthepredictedexcesstotalmedical
expenditureforyouthwithITDM,predicted
Table 1—Characteristics of study population by diabetes status and diabetes
treatment mode
Variables
Cases Controls Diabetes treatment mode
With diabetes Without diabetes ITDM NITDM
n 8,226 41,130 7,556 670
Mean age, years 12.87 (0.05) 12.78 (0.02) 12.70* (0.05) 14.84* (0.12)
Sex: girls, % 49.28 (0.55) 49.28 (0.25) 47.67* (0.57) 67.46* (1.81)
Census region, %
Midwest 30.46 (0.51) 30.46 (0.23) 30.72* (0.53) 27.61 (1.73)
South 43.54 (0.55) 43.54 (0.24) 42.79* (0.57) 52.09* (1.93)
West 16.42 (0.41) 16.42(0.18) 16.70*(0.43) 13.28*(1.31)
Urban residence, % 80.18 (0.44) 80.18 (0.20) 80.40 (0.46) 77.76 (1.61)
Non-PPO health plan, % 24.53 (0.47) 24.86 (0.21) 24.60 (0.50) 23.73 (1.64)
Asthma, % 4.55 (0.23) 4.36 (0.10) 4.09* (0.23) 9.70* (1.14)
Data are presented as mean (SE). *Statistically signiﬁcant (P , 0.05) comparison of means between groups
(youth with diabetes versus without diabetes, or ITDM versus NITDM).
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accounted for the largest proportion
($2,137; 59%), followed by expenditures
on inpatient ($712; 20%) and outpatient
care ($697; 19%). The expenditure on di-
abetes supplies was $863 for ITDM and
$82 for NITDM youth, and the expendi-
ture for diabetes medication was $1,826
for ITDM and $228 for NITDM youth
(data not shown).
CONCLUSIONS—The medical ex-
penditures associated with diabetes in
general and by diabetes treatment mode
among U.S. youth are less known. Using
administrative claims data from .3 mil-
lion youth, we estimated that the excess
mean total medical expenditure asso-
ciated with diabetes among youth was
$7,593 per year. Estimated mean annual
total medical expenditures were $9,333
for ITDM youth and $5,683 for NITDM
youth, an excess of $3,650 for those with
ITDM. Our ITDM group included all
youth with type 1 diabetes but probably
also some with type 2. Youth with
N I T D Mm o s tl i k e l yh a v et y p e2d i a b e t e s
(4,22–25), therefore, our estimated med-
ical expenditures for NITDM youth likely
represent a lower bound for youth with
type 2 diabetes receiving medications in
the U.S.
We found that excess expenditures
on prescription drugs contributed the
most to the total excess medical expendi-
tures associated with diabetes in youth.
This contrasts with ﬁndings for the entire
diabetic population, where hospitalization
or inpatient expenditures contributed the
most (5,8). However, our results of health
care spending across components are con-
sistentwiththeestimatesforacloselycom-
parable age group (#14 years) in Sweden
(8). Our relatively large expenditure on
prescription drugs was mainly driven
by a greater proportion of diabetic youth
who required treatment with insulin, thus
their greater expenses on insulin and di-
abetes supplies. This is consistent with
ﬁndings in Sweden (8).
We found that among diabetic youth
and regardless of treatment mode, the
drug expenses are mainly driven by the
expenses for medications. The expenses
for diabetic supplies are likely under-
estimated because not all health insur-
ance plans cover the costs of the diabetes
supplies.
Our estimated level of per capita total
medical expenditure attributable to di-
abetes of $7,593 is greater than a corre-
sponding per capita estimate of $6,649
for the entire U.S. diabetic population in
2007 (5). Our estimated total medical ex-
penditures ratio of those with diabetes
compared with those without diabetes is
also larger than that estimated for adults,
which ranges from 2 to 5 (5,7). However,
our estimated total medical expenditures
ratio is lower than in the previously men-
tioned Swedish study (8). Our results are
generally consistent with what has been
previously reported: excess expenditure
is higher in younger age groups, and the
expenditures ratio between persons with
orwithoutdiabetestendstodecreasewith
age (7,8). The higher excess expenditure
in younger age groups may have been
driven by costs for specialist visits, medi-
cations, and diabetes testing supplies (8).
The higher medical expenditures ratio for
youth may also have been driven by rela-
tively lower medical expenditures for
youthwithoutdiabetesthanthatforolder
populations without diabetes.
Our study has several limitations.
First, our medical claim data are from
enrollees in employer-sponsored health
plans and without uncommon chronic
conditions. The study population did not
include individuals without health insur-
ance coverage, those on Medicaid, and
those identiﬁed with uncommon chronic
conditions. Hence, the results may not be
generalized to the U.S. youth population.
Our sample only represents those en-
rolled in FFS plans and, therefore, may
not reﬂect medical expenditures for those
enrolled in capitated plans.
Second, the accuracy of our estimates
is subject to diagnostic coding errors;
however, the MarketScan database under-
goes rigorous data quality checks, and less




MarketScan database does not provide
sufﬁcientinformationtodifferentiatetype
1f r o mt y p e2d i a b e t e s .W ew e r ea l s o
unabletocorrectlyidentifydiabeticyouth
who were treated with diet and exercise
only; therefore, our sample does not in-
clude this population.
Our study showed that the excess
medical expenditures associated with di-
abetes in youth were substantial. Our
estimates associated with diabetes (both
ITDM and NITDM) can be used to esti-
mate the economic burden of diabetes in
youth in the U.S. The estimates of expen-
ditureforNITDMcanalsoserveasalower
bound to evaluate the beneﬁts of type 2
diabetes prevention programs. Future re-
search on estimation of costs among
youth with diabetes not on medications
would provide additional insights into
the expenditure associated with diabetes
among youth.
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Table 2—Predicted mean annual medical expenditures (U.S. $) in 2007 for U.S. youth by
diabetes status and treatment mode*
Diabetes status and treatment mode
Expenditure models
Total Outpatient Inpatient Drug
Diabetes vs. without diabetes†
With diabetes 9,061 (135) 3,939 (59) 1,628 (99) 3,505 (45)
Without diabetes 1,468 (29) 969 (21) 222 (16) 277 (6)
Excess: diabetes 7,593 (138) 2,970 (63) 1,406 (89) 3,228 (45)
Ratio 6.2 4.1 7.3 12.7
ITDM vs. NITDM‡
ITDM 9,333 (132) 3,997 (57) 1,688 (89) 3,629 (44)
NITDM 5,683 (487) 3,300 (287) 976 (244) 1,492 (150)
Excess: ITDM 3,650 (509) 697 (295) 712 (256) 2,137 (157)
Ratio 1.6 1.2 1.7 2.4
*All excess expenditures are statistically signiﬁcant (P , 0.05). Values in parentheses are bootstrap SE using
1,000 replications. Because of separate estimations of component models and rounding of values, the sum of
predicted medical expenditures across the components do not necessarily sum to total expenditures. †Co-
variates in all models are: health plan (PPO vs. non-PPO) and presence of asthma. ‡Covariates in all models
are:age,sex,censusregion,residence,healthplan,andpresenceofasthma.Referencegroupswereasfollows:
boys, northeast region, rural residence, PPO health plan, and without asthma.
1100 DIABETES CARE, VOLUME 34, MAY 2011 care.diabetesjournals.org
Medical expenditures of diabetes in youthPreliminary ﬁndings from this study were
presentedintheformofanoralpresentationat
the 70th Scientiﬁc Sessions of the American
DiabetesAssociation,Orlando,Florida,25–29
June 2010.
The authors thank Theodore Thompson,
the Chief of Statistics Section, and Robert
Gerzoff, Health System Analyst with the Di-
vision of Diabetes Translation, of the U.S.
CentersforDiseaseControlandPreventionfor
their statistical comments and programming
support.
References
1. Liese AD, D’Agostino RB Jr, Hamman RF,
et al.; SEARCH for Diabetes in Youth
Study Group. The burden of diabetes
mellitus among US youth: prevalence es-
timates from the SEARCH for Diabetes in
Youth Study. Pediatrics 2006;118:1510–
1518
2. Vehik K, Hamman RF, Lezotte D, et al.
Increasing incidence of type 1 diabetes
in 0- to 17-year-old Colorado youth. Di-
abetes Care 2007;30:503–509
3. Patterson CC, Dahlquist GG, Gyürüs E,
Green A, Soltész G; EURODIAB Study
Group. Incidence trends for childhood
type 1 diabetes in Europe during 1989-
2003 and predicted new cases 2005-20:
a multicentreprospectiveregistrationstudy.
Lancet 2009;373:2027–2033
4. Dabelea D, Bell RA, D’Agostino RB Jr,
et al.; Writing Group for the SEARCH for
DiabetesinYouthStudyGroup.Incidence
of diabetes in youth in the United States.
JAMA 2007;297:2716–2724
5. AmericanDiabetesAssociation.Economic
costs of diabetes in the U.S. In 2007. Di-
abetes Care 2008;31:596–615
6. Durden ED, Alemayehu B, Bouchard JR,
ChuBC,AagrenM.Directhealthcarecosts
of patients with type 2 diabetes within a
privately insured employed population,
2000 and 2005. J Occup Environ Med
2009;51:1460–1465
7. Ettaro L, Songer TJ, Zhang P, Engelgau
MM. Cost-of-illness studies in diabetes
mellitus. Pharmacoeconomics 2004;22:
149–164
8. Wiréhn AB, Andersson A, Ostgren CJ,
Carstensen J. Age-speciﬁcd i r e c th e a l t h -
care costs attributable to diabetes in a
Swedish population: a register-based anal-
ysis. Diabet Med 2008;25:732–737
9. Icks A, Rosenbauer J, Haastert B, et al.
Direct costs of pediatric diabetes care in
Germany and their predictors. Exp Clin
Endocrinol Diabetes 2004;112:302–309
10. Ying AK, Lairson DR, Giardino AP, et al.
Predictors of direct costs of diabetes care
in pediatric patients with type 1 diabetes.
PediatrDiabetes2010.doi:10.1111/j.1399-
5448.2010.00680.x
11. Centers for Disease Control and Pre-
vention. (2008). National diabetes fact
sheet: general information and national
estimates on diabetes in the United States,
2007. Atlanta, GA: U.S., Department of




12. Cohen FJ, Neslusan CA,Conklin JE, Song
X. Recent antihyperglycemic prescribing
trends for US privately insured patients
with type 2 diabetes. Diabetes Care 2003;
26:1847–1851
13. Rhoads GG, Orsini LS, Crown W, Wang
S, Getahun D, Zhang Q. Contribution
of hypoglycemia to medical care ex-
penditures and short-term disability in
employeeswithdiabetes.JOccupEnviron
Med 2005;47:447–452
14. Adamson DM, Chang S, Hansen LG.
Healthresearch datafor therealworld:the
MarketScan databases. White paper. Ann
Arbor,MI:ThomsonHealthcare,2008,1–32
15. The Medstat Group. Marketscan
(R) Re-
search Database: user guide and database
dictionary, 2005
16. Engelgau MM, Geiss LS, Manninen DL,
et al.; CDC Diabetes in Managed Care
Work Group. Use of services by diabetes
patients in managed care organizations.
Development of a diabetes surveillance
system.DiabetesCare1998;21:2062–2068
17. Mvundura M, Amendah D, Kavanagh PL,
Sprinz PG, Grosse SD. Health care utili-
zation and expenditures for privately and
publicly insured children with sickle cell
disease in the United States. Pediatr Blood
Cancer 2009;53:642–646
18. Gilmer TP, O’Connor PJ, Rush WA, et al.
Predictors of health care costs in adults
with diabetes. Diabetes Care 2005;28:
59–64
19. Diehr P, Yanez D, Ash A, Hornbrook M,
Lin DY. Methods for analyzing health care
utilization and costs. Annu Rev Public
Health 1999;20:125–144
20. Manning WG, Mullahy J. Estimating log
models: to transform or not to transform?
J Health Econ 2001;20:461–494
21. Flynn TN, Peters TJ. Use of the bootstrap
in analysing cost data from cluster ran-
domised trials: some simulation results.
BMC Health Serv Res 2004;4:33
22. Mayer-Davis EJ, Beyer J, Bell RA, et al.;
SEARCH for Diabetes in Youth Study
Group.DiabetesinAfricanAmericanyouth:
prevalence, incidence, and clinical charac-
teristics: the SEARCH for Diabetes in Youth
Study. Diabetes Care 2009;32(Suppl. 2):
S112–S122
23. Liu LL, Yi JP, Beyer J, et al.; SEARCH for
Diabetes in Youth Study Group. Type 1
and Type 2 diabetes in Asian and Paciﬁc
Islander U.S. youth: the SEARCH for Di-
abetes in Youth Study. Diabetes Care
2009;32(Suppl. 2):S133–S140
24. Lawrence JM, Mayer-Davis EJ, Reynolds
K, et al.; SEARCH for Diabetes in Youth
Study Group. Diabetes in Hispanic Amer-
ican youth: prevalence, incidence, demo-
graphics, and clinical characteristics: the
SEARCH for Diabetes in Youth Study.
Diabetes Care 2009;32(Suppl. 2):S123–
S132
25. Bell RA, Mayer-Davis EJ, Beyer JW, et al.;
SEARCH for Diabetes in Youth Study
Group. Diabetes in non-Hispanic white
youth: prevalence, incidence, and clinical
characteristics: the SEARCH for Diabetes
in Youth Study. Diabetes Care 2009;32
(Suppl. 2):S102–S111
care.diabetesjournals.org DIABETES CARE, VOLUME 34, MAY 2011 1101
Shrestha and Associates